DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rasburicase
Rasburicase
Trade-To-Generic Names
AHFS Pharmacologic-Therapeutic Classification System
BC Cancer Protocol Summary for Treatment of Lymphoma with Dose- Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide
Rasburicase (Elitek)
Approved Cancer Drugs for Children
Estonian Statistics on Medicines 2016 1/41
Chapter 4: Tumor Lysis Syndrome
Nebraska Medicine IV Push Medication Review
Standard Oncology Criteria C16154-A
Chlorambucil
Febuxostat for Management of Tumor Lysis Syndrome Including Its Effects
Treating Non-Hodgkin Lymphoma If You’Ve Been Diagnosed with Non-Hodgkin Lymphoma, Your Treatment Team Will Discuss Your Options with You
Application to Add Rasburicase to WHO Model List of Essential Medicines
Estonian Statistics on Medicines 2013 1/44
Fasturtec, INN-Rasburicase
Procedure Codes, Section 3
The Cost Burden of Blood Cancer Care a Longitudinal Analysis of Commercially Insured Patients Diagnosed with Blood Cancer
DRUG NAME: Cyclophosphamide
Top View
Effectiveness of a Single 3-Mg Rasburicase Dose for the Management of Hyperuricemia in Patients with Hematological Malignancies
R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt’S and Atypical Burkitt’S Lymphoma
Things We Do for No Reason™: Rasburicase for Adult Patients with Tumor Lysis Syndrome
Fasturtec (Raburicase)
DRUG NAME: Methotrexate
Biopharmaceutical Benchmarks 2018
Rasburicase for Adults with Acute Tumor Lysis Syndrome: a Review of Clinical and Cost Effectiveness and Safety
Table III 2021 Medicare National Drug Fee Schedule
DRUG NAME: Idarubicin
Instructional Template for Therapeutic Protocol
Tumor Lysis Syndrome(TLS) Treatment Guidelines
Fasturtec, Powder for Infusion
Chemistry Test Name: URIC ACID, PATIENT on RASBURICASE
Is Rasburicase an Effective Alternative to Allopurinol for Management of Hyperuricemia in Renal Failure Patients? a Double Blind-Randomized Study
Management of CKD and AKI in Malignancy
Supportive Care in the Management of T-Cell Lymphomas
Reduced-Dose Rasburicase (Recombinant Xanthine Oxidase) in Adult Cancer Patients with Hyperuricemia
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: an Evidence-Based Update
(R) Codox-M (R) Ivac
Tumor Lysis Syndrome (Amended July 2006)
Cancer Chemotherapy
Tumour Lysis Syndrome in Adults
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
Via Electronic Submission January 10, 2020 Jeffrey Bailet, MD Committee Chair Physician-Focused Payment Model Technical Advisory
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Statistics on Medicines Consumption 2009
Guidelines for Use of RASBURICASE in Adult Haematology and Oncology Patients
Recognizing and Managing the Expanded Risk of Tumor Lysis Syndrome in Hematologic and Solid Malignancies Ali Mcbride1* and Peter Westervelt2
Pitfalls, Prevention, and Treatment of Hyperuricemia During Tumor Lysis Syndrome in the Era of Rasburicase (Recombinant Urate Oxidase)
Gemcitabine, Cisplatin, Dexamethasone
Supportive Care Agents
Code Description Max Qty Rate Comments/Notes J0207 Amifostine 500Mg 3 469.48 J0594 Busulfan 1Mg 60 32.49 J0640 Leucovorin Calciu
30400905 Rasburicase (Elitek) for Tumor Lysis Syndrome (905
Tumor Lysis Syndrome (TLS) in Adult Patients
Guidelines for ATC Classification and DDD Assignment 2021
Generic-To-Trade Names
AHFS Pharmacologic-Therapeutic Classification System
Acute Leukaemias and Myeloid Neoplasms Part 2: Acute Myeloid Leukaemia
Inp RCODOX M(66) Cyclophosphamide Doxorubicin Methotrexate Rituximab Vincristine
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Biologics and Biosimilars: Background and Key Issues
Guidelines for ATC Classification and DDD Assignment 2013
Rasburicase for Tophaceous Gout Not Treatable with Allopurinol: an Exploratory Study
Do Not Tube List
Rare Case of Spontaneous Tumor Lysis Syndrome (TLS) in a Patient with Germ Cell Tumor (GCT): Literature Review and Approach to Management
NSSG Chemotherapy Protocol
DRUG NAME: Daunorubicin
Economics of New Oncology Drug Development Joseph A
A.27 Rasburicase – Treatment and Prevention of Tumour Lysis Syndrome
REVIEW Elitektm–Rasburicase: an Effective Means to Prevent and Treat
Resolution Ap (2000) 1
What Is the Incidence of Kidney Stones After Chemotherapy in Patients with Lymphoproliferative Or Myeloproliferative Disorders? ______
Evaluation of Fixed Dosing of New Anticancer Agents in Phase I Studies DOMINIQUE LEVÊQUE
Highlights of Prescribing Information